AIMLF
AI / ML INNOVATIONS INC
stock OTC

* **CSE: AIML / OTCQB: AIMLF:** recently traded around **CA$0.055–CA$0.06 / US$0.04**, with market cap around **CA$14.9M / US$10.2M**.
* **Latest catalyst:** AIML appointed **Dr. Martin Stephen Green** to its Medical Advisory Board, effective **April 27, 2026**.
* **Investor angle:** AIML is strengthening clinical validation around its AI-driven ECG signal-processing platform as it pushes toward regulatory, scientific, and commercial milestones.
AI/ML Innovations Inc. (**CSE: AIML / OTCQB: AIMLF / FWB: 42FB**) is trying to build a focused position in AI-powered cardiac data. The company’s latest news is not a product launch or financing headline. It is a clinical credibility update: AIML has appointed **Dr. Martin Stephen Green, MD, FRCPC**, Professor Emeritus at the University of Ottawa, to its Medical Advisory Board.
For a micro-cap healthcare AI company, that matters. **AIMLF** is still early-stage, but its NeuralCloud strategy depends on proving that AI can handle real ECG and Holter data with the level of clinical rigor needed for research, validation, and eventual deployment. Adding a physician with decades of electrocardiography and electrophysiology experience strengthens the medical side of that story.
**Market Catalyst: ECG AI Needs Clinical Trust**
AI in healthcare is moving from concept to workflow, but cardiac AI faces a higher bar than ordinary software. ECG and Holter data are used in clinical decision-making, which means accuracy, validation, physician trust, and regulatory strategy matter. That is why medical advisory depth can become important for companies trying to commercialize AI-powered signal-processing tools.
The broader market setup is still attractive. Healthcare AI has been estimated at roughly **US$26.6B in 2024**, with forecasts pointing to high double-digit annual growth through the end of the decade. Cardiovascular disease remains one of the world’s largest healthcare burdens, responsible for roughly **17.9M deaths per year**, while Holter monitoring can generate **24 hours to 14 days** of continuous rhythm data per patient.
Two numbers show why AIML’s ECG focus matters:
* **Holter and ECG workflows create large volumes of time-series data**, where automation, signal cleaning, beat labeling, and interval measurement could reduce review bottlenecks.
* **AIML has roughly 271.1M shares outstanding on the CSE**, making it a micro-cap stock where clinical validation and commercialization milestones can materially change investor perception.
The opportunity is clear, but so is the risk. AI healthcare companies need more than good technology. They need clinicians, research partners, regulatory discipline, commercial pathways, and enough capital to execute.
**The Latest News: Dr. Martin Green Joins AIML**
AIML announced that Dr. Martin Green has joined its Medical Advisory Board at the invitation of **Dr. Paul Dorian**, AIML’s Medical Innovation Architect and Chair of the Medical Advisory Board. The two physicians have collaborated for more than **three decades** across the Canadian Registry of Atrial Fibrillation, Canadian Cardiovascular Society guideline work, and peer-reviewed publications.
* **Investor data point:** Dr. Green brings roughly **45 years** of ECG and Holter interpretation experience and has authored or co-authored more than **230 peer-reviewed publications**.
Dr. Green founded the Arrhythmia Service at the University of Ottawa Heart Institute in **1983** and built it into a national referral centre. He served as Director of the EP Fellowship Program from **1983 to 2017**, Director of the ECG Department from **1983 to 2018**, and Director of the Inherited Arrhythmia Clinic from **2013 to 2022**.
For **AIMLF**, the appointment adds direct clinical depth in the exact area NeuralCloud is targeting: ECG signal processing, Holter analysis, arrhythmia workflows, and physician-grade interpretation standards.
**Dr. Martin Green commented:**
https://preview.redd.it/p51nx1f66a2h1.png?width=1340&format=png&auto=webp&s=8c7cab67dbca3a593a586d488e40696dace2f8aa
**Why This Matters for NeuralCloud**
AIML’s core investor story is tied to NeuralCloud and its MaxYield™ ECG signal-processing platform. The company has described MaxYield™ as a system designed to convert raw or legacy ECG data into structured, machine-readable formats, isolate and label ECG waveform components, and generate beat-level data and interval measurements.
That sounds technical, but the investment point is simple. If **AIML / AIMLF** can help researchers, clinics, hospitals, or monitoring platforms process ECG and Holter data more efficiently, the company could move from concept-stage AI healthcare story toward a more commercially relevant medical-data platform.
Dr. Green’s addition does not prove commercial adoption by itself. But it supports the validation path. A company selling AI into cardiac workflows needs recognized clinicians who understand where current ECG platforms fall short and what physicians need from the next generation of tools.
**Medical Advisory Board Is Becoming a Bigger Asset**
The release says AIML’s Medical Advisory Board now extends across three major Canadian cardiac centres: **St. Michael’s Hospital in Toronto**, **St. Paul’s Hospital in Vancouver**, and the **University of Ottawa Heart Institute**. That gives AIML broader national clinical coverage as it advances clinical studies, regulatory strategy, and real-world deployment.
AIML established its Medical Advisory Board in **May 2025**, and Dr. Dorian was appointed Medical Innovation Architect and Head of the board in **January 2026**. The addition of Dr. Green builds on that structure and gives **AIMLF** another recognized cardiology figure at a time when the company is trying to show its ECG-AI platform can be clinically credible.
**Stock Snapshot**
https://preview.redd.it/b3g0bzx76a2h1.png?width=1476&format=png&auto=webp&s=70059a6c5f0b1ee86344b2f941ba00c8fda41509
**What Investors Should Watch**
The next step for **AIMLF** is proof that clinical credibility turns into commercial progress. Investors should watch for more research services agreements, hospital or clinic pilots, regulatory updates, Holter-reporting integrations, reseller partnerships, and recurring revenue.
Investors should also watch dilution. The company announced **4,000,000** stock options exercisable at **$0.10** for **five years**, while the CSE lists a large reserved-for-issuance figure. That is normal for many micro-caps, but it matters because the upside case depends on execution outpacing dilution.
**Bottom Line**
AIML’s appointment of Dr. Martin Green strengthens the clinical foundation behind its ECG-AI strategy. For **AIMLF**, this is a credibility catalyst rather than an immediate revenue event.
The key question is whether AIML can convert medical advisory depth into validation, partnerships, regulatory progress, and commercial adoption for NeuralCloud’s MaxYield™ platform.
***This is sponsored content. Investors should conduct their own due diligence and consult a qualified financial advisor before making any investment decisions.***

* **CSE: AIML / OTCQB: AIMLF:** recently traded around **CA$0.055–CA$0.06 / US$0.04**, with market cap around **CA$14.9M / US$10.2M**.
* **Latest catalyst:** AIML appointed **Dr. Martin Stephen Green** to its Medical Advisory Board, effective **April 27, 2026**.
* **Investor angle:** AIML is strengthening clinical validation around its AI-driven ECG signal-processing platform as it pushes toward regulatory, scientific, and commercial milestones.
AI/ML Innovations Inc. (**CSE: AIML / OTCQB: AIMLF / FWB: 42FB**) is trying to build a focused position in AI-powered cardiac data. The company’s latest news is not a product launch or financing headline. It is a clinical credibility update: AIML has appointed **Dr. Martin Stephen Green, MD, FRCPC**, Professor Emeritus at the University of Ottawa, to its Medical Advisory Board.
For a micro-cap healthcare AI company, that matters. **AIMLF** is still early-stage, but its NeuralCloud strategy depends on proving that AI can handle real ECG and Holter data with the level of clinical rigor needed for research, validation, and eventual deployment. Adding a physician with decades of electrocardiography and electrophysiology experience strengthens the medical side of that story.
**Market Catalyst: ECG AI Needs Clinical Trust**
AI in healthcare is moving from concept to workflow, but cardiac AI faces a higher bar than ordinary software. ECG and Holter data are used in clinical decision-making, which means accuracy, validation, physician trust, and regulatory strategy matter. That is why medical advisory depth can become important for companies trying to commercialize AI-powered signal-processing tools.
The broader market setup is still attractive. Healthcare AI has been estimated at roughly **US$26.6B in 2024**, with forecasts pointing to high double-digit annual growth through the end of the decade. Cardiovascular disease remains one of the world’s largest healthcare burdens, responsible for roughly **17.9M deaths per year**, while Holter monitoring can generate **24 hours to 14 days** of continuous rhythm data per patient.
Two numbers show why AIML’s ECG focus matters:
* **Holter and ECG workflows create large volumes of time-series data**, where automation, signal cleaning, beat labeling, and interval measurement could reduce review bottlenecks.
* **AIML has roughly 271.1M shares outstanding on the CSE**, making it a micro-cap stock where clinical validation and commercialization milestones can materially change investor perception.
The opportunity is clear, but so is the risk. AI healthcare companies need more than good technology. They need clinicians, research partners, regulatory discipline, commercial pathways, and enough capital to execute.
**The Latest News: Dr. Martin Green Joins AIML**
AIML announced that Dr. Martin Green has joined its Medical Advisory Board at the invitation of **Dr. Paul Dorian**, AIML’s Medical Innovation Architect and Chair of the Medical Advisory Board. The two physicians have collaborated for more than **three decades** across the Canadian Registry of Atrial Fibrillation, Canadian Cardiovascular Society guideline work, and peer-reviewed publications.
* **Investor data point:** Dr. Green brings roughly **45 years** of ECG and Holter interpretation experience and has authored or co-authored more than **230 peer-reviewed publications**.
Dr. Green founded the Arrhythmia Service at the University of Ottawa Heart Institute in **1983** and built it into a national referral centre. He served as Director of the EP Fellowship Program from **1983 to 2017**, Director of the ECG Department from **1983 to 2018**, and Director of the Inherited Arrhythmia Clinic from **2013 to 2022**.
For **AIMLF**, the appointment adds direct clinical depth in the exact area NeuralCloud is targeting: ECG signal processing, Holter analysis, arrhythmia workflows, and physician-grade interpretation standards.
**Dr. Martin Green commented:**
https://preview.redd.it/p51nx1f66a2h1.png?width=1340&format=png&auto=webp&s=8c7cab67dbca3a593a586d488e40696dace2f8aa
**Why This Matters for NeuralCloud**
AIML’s core investor story is tied to NeuralCloud and its MaxYield™ ECG signal-processing platform. The company has described MaxYield™ as a system designed to convert raw or legacy ECG data into structured, machine-readable formats, isolate and label ECG waveform components, and generate beat-level data and interval measurements.
That sounds technical, but the investment point is simple. If **AIML / AIMLF** can help researchers, clinics, hospitals, or monitoring platforms process ECG and Holter data more efficiently, the company could move from concept-stage AI healthcare story toward a more commercially relevant medical-data platform.
Dr. Green’s addition does not prove commercial adoption by itself. But it supports the validation path. A company selling AI into cardiac workflows needs recognized clinicians who understand where current ECG platforms fall short and what physicians need from the next generation of tools.
**Medical Advisory Board Is Becoming a Bigger Asset**
The release says AIML’s Medical Advisory Board now extends across three major Canadian cardiac centres: **St. Michael’s Hospital in Toronto**, **St. Paul’s Hospital in Vancouver**, and the **University of Ottawa Heart Institute**. That gives AIML broader national clinical coverage as it advances clinical studies, regulatory strategy, and real-world deployment.
AIML established its Medical Advisory Board in **May 2025**, and Dr. Dorian was appointed Medical Innovation Architect and Head of the board in **January 2026**. The addition of Dr. Green builds on that structure and gives **AIMLF** another recognized cardiology figure at a time when the company is trying to show its ECG-AI platform can be clinically credible.
**Stock Snapshot**
https://preview.redd.it/b3g0bzx76a2h1.png?width=1476&format=png&auto=webp&s=70059a6c5f0b1ee86344b2f941ba00c8fda41509
**What Investors Should Watch**
The next step for **AIMLF** is proof that clinical credibility turns into commercial progress. Investors should watch for more research services agreements, hospital or clinic pilots, regulatory updates, Holter-reporting integrations, reseller partnerships, and recurring revenue.
Investors should also watch dilution. The company announced **4,000,000** stock options exercisable at **$0.10** for **five years**, while the CSE lists a large reserved-for-issuance figure. That is normal for many micro-caps, but it matters because the upside case depends on execution outpacing dilution.
**Bottom Line**
AIML’s appointment of Dr. Martin Green strengthens the clinical foundation behind its ECG-AI strategy. For **AIMLF**, this is a credibility catalyst rather than an immediate revenue event.
The key question is whether AIML can convert medical advisory depth into validation, partnerships, regulatory progress, and commercial adoption for NeuralCloud’s MaxYield™ platform.
***This is sponsored content. Investors should conduct their own due diligence and consult a qualified financial advisor before making any investment decisions.***